PMID- 37748107
OWN - NLM
STAT- MEDLINE
DCOM- 20230927
LR  - 20231009
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 55
IP  - 2
DP  - 2023
TI  - Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy 
      for relapsed or refractory diffuse large B-cell lymphoma.
PG  - 2261109
LID - 10.1080/07853890.2023.2261109 [doi]
LID - 2261109
AB  - OBJECTIVES: To compare the efficacy and side effects of salvage chemotherapy 
      between etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP) and 
      ifosfamide, carboplatin and etoposide plus dexamethasone (DICE) for relapsed or 
      refractory diffuse large B-cell lymphoma (DLBCL). METHODS: Medical records of 
      patients with relapsed or refractory DLBCL receiving second-line ESHAP or DICE 
      chemotherapy with or without rituximab from January 2007 to November 2022 were 
      retrospectively reviewed. The primary objective was progression-free survival 
      (PFS). The secondary objectives were overall survival (OS), overall response rate 
      (ORR) and adverse events (AEs). RESULTS: Seventy patients were enrolled including 
      21 patients who received ESHAP and 49 patients who received the DICE regimen. Six 
      patients (28.6%) and 19 patients (38.8%) in the ESHAP and DICE groups underwent 
      ASCT, respectively. The ORR was 47.6% for ESHAP and 53.1% for DICE (p = .67). The 
      two-year PFS was 14.3% for ESHAP and 26.5% for DICE (p = .33) with median PFS of 
      5 months and 14 months, respectively (hazard ratio 0.74; 95% CI 0.39-1.36, 
      p = .330). The two-year OS was 14.3% for ESHAP and 26.5% for DICE (p = .37) with 
      median OS of 8 months and 19 months, respectively. Patients in ESHAP group have 
      more all-grade renal impairment than DICE group (23.8% vs. 6.1%, p = .047). 
      DISCUSSION AND CONCLUSIONS: Efficacy between ESHAP and DICE regimens as salvage 
      chemotherapy for relapsed or refractory DLBCL was not significantly different in 
      terms of two-year PFS, two-year OS and ORR. DICE regimen had less renal AE than 
      ESHAP.
FAU - Boonlerd, Pattamaporn
AU  - Boonlerd P
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Tantiworawit, Adisak
AU  - Tantiworawit A
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Norasetthada, Lalita
AU  - Norasetthada L
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Chai-Adisaksopha, Chatree
AU  - Chai-Adisaksopha C
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Punnachet, Teerachat
AU  - Punnachet T
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Hantrakun, Nonthakorn
AU  - Hantrakun N
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Piriyakhuntorn, Pokpong
AU  - Piriyakhuntorn P
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Rattanathammethee, Thanawat
AU  - Rattanathammethee T
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Hantrakool, Sasinee
AU  - Hantrakool S
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
FAU - Rattarittamrong, Ekarat
AU  - Rattarittamrong E
AUID- ORCID: 0000-0002-7819-5544
AD  - Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 
      Chiang Mai, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20230925
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - Q20Q21Q62J (Cisplatin)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 04079A1RDZ (Cytarabine)
RN  - X4W7ZR7023 (Methylprednisolone)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Humans
MH  - *Cisplatin/adverse effects
MH  - Etoposide/adverse effects
MH  - Retrospective Studies
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Cytarabine/adverse effects
MH  - Methylprednisolone
MH  - Dexamethasone/adverse effects
PMC - PMC10521335
OTO - NOTNLM
OT  - DICE chemotherapy
OT  - ESHAP chemotherapy
OT  - ICE chemotherapy
OT  - Relapsed or refractory diffuse large B-cell lymphoma
OT  - diffuse large B-cell lymphoma
OT  - lymphoma
COIS- The authors report there are no competing interests to declare.
EDAT- 2023/09/25 18:41
MHDA- 2023/09/27 06:42
PMCR- 2023/09/25
CRDT- 2023/09/25 16:03
PHST- 2023/09/27 06:42 [medline]
PHST- 2023/09/25 18:41 [pubmed]
PHST- 2023/09/25 16:03 [entrez]
PHST- 2023/09/25 00:00 [pmc-release]
AID - 2261109 [pii]
AID - 10.1080/07853890.2023.2261109 [doi]
PST - ppublish
SO  - Ann Med. 2023;55(2):2261109. doi: 10.1080/07853890.2023.2261109. Epub 2023 Sep 
      25.